CD4 and hepatocellular carcinoma: Regarding specific functional subsets, Pinato et al. found in 13 HCC patients treated with TACE combined with pembrolizumab that responders (CR/PR) had a cluster of Th1-like CD4+ T cells characterized by high expression of T-bet, CX3CR1, KLRG1, and CD57 at baseline, whereas non-responders showed enrichment of central memory CD4+ T cell (TCF-1+CCR7+CD4+ T) at baseline [116].